Science & academia

This archive covers milestones and breakthroughs from the scientific and academic world — researchers, universities, and institutions whose work advances human knowledge. Stories here highlight discoveries, studies, and scholarly efforts that point toward a better future.

Space solar transmission project, for article on space solar power

China builds world-first full-function space solar verification tower

Space solar power just cleared a milestone that researchers once thought was still years away. China’s test tower at Xidian University is the first facility anywhere to run the complete chain — concentrating sunlight, converting it to electricity, and beaming that power wirelessly to a ground receiver — all in one integrated system, completed roughly three years ahead of schedule. It’s a research milestone, not a power plant, but proving the full system works in one place gives scientists a permanent platform to push the technology forward.

Vials of blood, for article on cancer diagnostics Africa, for article on Parkinson's blood test

First-of-a-kind blood test paves way for early Parkinson’s diagnosis

A simple blood test that could catch Parkinson’s disease before symptoms take hold is now closer to reality. Researchers at Kobe University developed an assay that reads changes in enzyme activity in a blood sample, achieving 85 to 88 percent accuracy in both human and rat models. Because treatments like levodopa and exercise work better early in the disease’s progression, earlier detection could meaningfully change what’s possible for patients. With Parkinson’s cases more than doubling globally over the past 25 years, affordable, scalable screening tools like this one could reshape how the world responds to the fastest-growing neurological disorder.

Micro X-ray of mushrooms with false colors, for article on psilocybin clinical trials

First European psychedelic drug trial clinic opens in the U.K.

Clerkenwell Health’s opening marks a turning point for psychedelic medicine, moving it from university labs into dedicated commercial infrastructure built to carry promising compounds through late-stage clinical trials. The clinic’s first focus is patients facing terminal diagnoses — a population where conventional treatments often fall short, and where earlier psilocybin studies showed lasting reductions in anxiety and depression after just one or two sessions. By serving multiple drug developers at once, the facility could meaningfully accelerate how quickly different psychedelic compounds reach the people who need them. It’s a signal that this field is ready to scale.